Insider Buying: Rezolute, Inc. (NASDAQ:RZLT) Director Acquires 6,758 Shares of Stock

Rezolute, Inc. (NASDAQ:RZLT) Director Wladimir Hogenhuis bought 6,758 shares of the business’s stock in a transaction dated Monday, March 31st. The shares were acquired at an average cost of $2.92 per share, for a total transaction of $19,733.36. Following the purchase, the director now owns 84,025 shares of the company’s stock, valued at approximately $245,353. The trade was a 8.75 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Wladimir Hogenhuis also recently made the following trade(s):

• On Tuesday, February 18th, Wladimir Hogenhuis acquired 10,000 shares of Rezolute stock. The shares were acquired at an average price of $4.70 per share, with a total value of $47,000.00.

Rezolute Stock Performance

NASDAQ RZLT opened at $2.92 on Wednesday. Rezolute, Inc. has a one year low of $2.22 and a one year high of $6.19. The company has a market capitalization of $176.76 million, a price-to-earnings ratio of -2.39 and a beta of 0.95. The company’s 50-day simple moving average is $4.18 and its two-hundred day simple moving average is $4.72.

Rezolute (NASDAQ:RZLT) last issued its quarterly earnings data on Wednesday, February 12th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.33) by $0.11. Equities analysts expect that Rezolute, Inc. will post -0.93 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Alpine Global Management LLC bought a new stake in Rezolute during the fourth quarter valued at about $54,000. Woodline Partners LP lifted its position in shares of Rezolute by 2,817.1% during the fourth quarter. Woodline Partners LP now owns 1,089,345 shares of the company’s stock valued at $5,338,000 after buying an additional 1,052,002 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. boosted its holdings in shares of Rezolute by 48.5% in the 4th quarter. Point72 Asia Singapore Pte. Ltd. now owns 19,799 shares of the company’s stock valued at $97,000 after buying an additional 6,470 shares in the last quarter. Point72 Europe London LLP purchased a new position in shares of Rezolute in the 4th quarter worth approximately $720,000. Finally, Man Group plc bought a new position in shares of Rezolute during the 4th quarter worth approximately $425,000. 82.97% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

RZLT has been the topic of a number of recent analyst reports. Craig Hallum upgraded Rezolute to a “strong-buy” rating in a research note on Tuesday, February 4th. Guggenheim reaffirmed a “buy” rating on shares of Rezolute in a research note on Monday, February 10th. HC Wainwright reissued a “buy” rating and issued a $14.00 price objective on shares of Rezolute in a research report on Thursday, February 13th. Finally, JMP Securities raised their target price on shares of Rezolute from $8.00 to $9.00 and gave the stock a “market outperform” rating in a research report on Thursday, February 13th. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $24.38.

Rezolute Company Profile

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.